FOXO

send to a friend share this

Harmine and Piperlongumine Revert TRIB2-Mediated Drug Resistance

Poor survival and treatment failure of patients with cancer are mainly due to therapy resistance. Tribbles homologue 2 (TRIB2) has recently been identified as a protein that promotes resistance to several anti-cancer drugs. In this study, RNA sequencing and bioinformatics analysis were used to characterise the impact of TRIB2 on the expression of genes and develop pharmacological strategies to revert these TRIB2-mediated changes, thereby overcoming therapy resistance.

Harmine and Piperlongumine Revert TRIB2-Mediated Drug Resistance

Poor survival and treatment failure of patients with cancer are mainly due to therapy resistance. Tribbles homologue 2 (TRIB2) has recently been identified as a protein that promotes resistance to several anti-cancer drugs. In this study, RNA sequencing and bioinformatics analysis were used to characterise the impact of TRIB2 on the expression of genes and develop pharmacological strategies to revert these TRIB2-mediated changes, thereby overcoming therapy resistance.

Discovery of a Novel, Isothiazolonaphthoquinone-Based Small Molecule Activator of FOXO Nuclear-Cytoplasmic Shuttling

Authors and Affiliations:

Bastien Cautain1, Francisco Castillo1, Loana Musso2, Bibiana I. Ferreira3,4, Nuria de Pedro1, Lorena Rodriguez Quesada1, Susana Machado3, Francisca Vicente1, Sabrina Dallavalle2, Wolfgang Link3,4

1 Fundacion MEDINA, Parque Tecnológico Ciencias de la Salud, Granada, Spain, 

Investigadores do CBMR descobrem composto químico que pode ser usado como arma nos tumores humanos

Uma equipa de investigadores do Centro de Investigação em Biomedicina, liderada por Wolfgang Link e composta por investigadores nacionais e internacionais, entre os quais Bibiana Ferreira e Susana Machado, também investigadoras do CBMR, acaba de publicar um inovador artigo científico na revista científica PLOS ONE, uma das mais conceituadas revistas internacionais de acesso aberto na área das ciências e da medicina.

 

The challenge of diagnosing a malignancy metastatic to the ovary

João Lobo 1,2,3, Bianca Machado 1, Renata Vieira 1, Carla Bartosch 1,2,4

1 Department of Pathology, Portuguese Oncology Institute-Porto, Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal

2 Cancer Biology and Epigenetics Group, Research Center (CI-IPOP), Portuguese Oncology Institute of Porto, Porto, Portugal